“GLP-1 Agonists for Inflammation: Semaglutide’s Anti-Inflammatory Potential”

Yes, GLP-1 receptor agonists such as semaglutide lower measurable inflammation: in the SELECT trial, semaglutide 2.4 mg once weekly reduced high-sensitivity C-reactive protein (hsCRP) by 37.8% more than placebo and cut major cardiovascular events by 20% (Lincoff et al., New England Journal of Medicine, 2023). The effect comes partly from weight loss and partly from GLP-1 receptors on immune cells, blood vessels and the liver, yet no GLP-1 drug is approved as a general anti-inflammatory treatment.

Do GLP-1 Agonists Reduce Inflammation?

GLP-1 agonists reduce inflammation in people with obesity, type 2 diabetes and cardiovascular disease, the groups in which they have been studied. The clearest signal is hsCRP, a blood marker of whole-body inflammation, which fell by 37.8% relative to placebo in the SELECT trial of semaglutide [4]. Similar drops in hsCRP appeared in the STEP-HFpEF heart failure trial (Kosiborod et al., 2023).

Lower inflammatory markers are a measurement, not a treatment claim. No GLP-1 drug is approved by the US Food and Drug Administration (FDA) to treat inflammation as a stand-alone problem, and there is little trial data in people who are lean and metabolically healthy. The table below summarizes where the evidence stands for each condition.

Beyond Blood Sugar and Weight Loss

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide, dulaglutide) were developed to treat type 2 diabetes by mimicking the incretin hormone GLP-1, which stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. Their large weight loss effects (12 to 18% body weight reduction with semaglutide) made them the most talked-about drug class in a generation, according to a review by Daniel Drucker (Cell Metabolism, 2018) [1].

Something else showed up in the clinical trials: significant reductions in inflammatory biomarkers that could not be fully explained by weight loss alone. Researchers are now investigating whether GLP-1 agonists represent a new class of anti-inflammatory agent with applications far beyond diabetes and obesity.

The drug names overlap, which confuses many readers. Semaglutide is sold as a weekly injection for diabetes (Ozempic), a higher-dose weekly injection for weight management and cardiovascular risk reduction (Wegovy) and an oral tablet. Tirzepatide is a dual GIP and GLP-1 receptor agonist, and our comparison of semaglutide and tirzepatide covers how the two differ. Compounded semaglutide and compounded tirzepatide are pharmacy-made versions that are not FDA approved and have not been tested in the inflammation trials described below.

The Anti-Inflammatory Evidence

Inflammatory Biomarker Reductions

Multiple trials of GLP-1 agonists have measured inflammatory markers:

• High-sensitivity CRP (hsCRP): The SELECT trial (semaglutide in overweight or obese adults without diabetes but with cardiovascular disease) showed a 37.8% reduction in hsCRP compared to placebo, and the reduction was sustained through 104 weeks [4]. CRP is a marker of systemic inflammation and an independent predictor of cardiovascular events.
• IL-6: Multiple studies show reductions in interleukin-6, a key pro-inflammatory cytokine involved in the acute-phase response and chronic inflammatory pathways. Ridker and colleagues (European Heart Journal, 2020) showed that IL-6 still tracks cardiovascular risk even after another inflammatory pathway is blocked, which is why researchers watch it closely [2].
• TNF-alpha: Reductions observed in clinical studies, though the magnitude varies.
• PAI-1 and fibrinogen: Reduced, suggesting decreased thrombotic risk and inflammation of the vascular endothelium.

Some of these reductions appear to exceed what weight loss alone would explain. In mice, Rakipovski and colleagues (2018) found that semaglutide and liraglutide slowed atherosclerosis through inflammatory pathways rather than through weight or cholesterol changes [3]. In humans, the case for a weight-independent effect is suggestive rather than settled, because weight loss and lower inflammation happen at the same time.

The SELECT Trial: Cardiovascular Evidence

The SELECT trial, published in the New England Journal of Medicine in 2023, was a landmark study. It enrolled 17,604 adults aged 45 and older with established cardiovascular disease and overweight or obesity but without diabetes. Participants received semaglutide 2.4 mg weekly or placebo [4]. The full SELECT paper in the New England Journal of Medicine lists the outcomes in detail.

Results:

• 20% reduction in major adverse cardiovascular events (MACE: cardiovascular death, non-fatal heart attack, non-fatal stroke)
• Event curves separated early and the difference persisted through more than three years of follow-up
• Cardiovascular benefit appeared before maximal weight loss occurred
• Later SELECT analyses found the benefit was similar across starting body weights and did not depend closely on how much weight people lost

This pattern suggests that semaglutide’s cardiovascular protection is driven partly by mechanisms other than weight loss, and lower inflammation is the leading candidate. The anti-inflammatory arm of the benefit may be as important as the metabolic arm, though SELECT was not designed to separate the two.

How GLP-1 Agonists Reduce Inflammation

GLP-1 agonists reduce inflammation through four main routes: they calm immune cells directly, protect the lining of blood vessels, shrink inflamed visceral fat and strengthen the gut barrier. These routes work together, which is why the effect shows up in the heart, liver and kidneys at once.

GLP-1 receptors are not limited to pancreatic beta cells. They are expressed throughout the body, including on immune cells, endothelial cells, cardiomyocytes, neurons, and hepatocytes. This widespread receptor distribution enables multiple anti-inflammatory mechanisms [5]:

Direct Immune Cell Modulation

GLP-1 receptor activation on macrophages shifts them from a pro-inflammatory M1 phenotype toward an anti-inflammatory M2 phenotype. M1 macrophages produce TNF-alpha, IL-1beta, and IL-6 (driving chronic inflammation). M2 macrophages produce IL-10 and TGF-beta (resolving inflammation and promoting tissue repair).

GLP-1 agonists also reduce T-cell activation and proliferation, decrease monocyte adhesion to endothelial cells (a key step in atherosclerotic plaque formation), and inhibit NF-kB signaling (the master regulator of inflammatory gene expression).

Endothelial Protection

GLP-1 receptor activation in endothelial cells increases nitric oxide production, reduces oxidative stress, and inhibits endothelial adhesion molecule expression (VCAM-1, ICAM-1). This makes the vascular lining less “sticky” to inflammatory cells and more resistant to atherosclerotic plaque initiation.

Adipose Tissue Inflammation

Excess visceral fat is a factory for inflammatory cytokines. GLP-1 agonists preferentially reduce visceral fat (which is more metabolically active and inflammatory than subcutaneous fat), decreasing the adipose tissue contribution to systemic inflammation. Beyond fat reduction, GLP-1 signaling in adipocytes directly reduces cytokine secretion.

Gut Barrier and Microbiome

GLP-1 agonists improve intestinal barrier integrity, reducing bacterial endotoxin (LPS) translocation into the bloodstream. Chronic low-grade endotoxemia from a leaky gut is a recognized driver of metabolic inflammation. By strengthening the gut barrier, GLP-1 agonists address inflammation at one of its sources. Much of this gut evidence comes from animal studies, so it is the least certain of the four routes.

How does Wegovy reduce inflammation?

Wegovy is semaglutide 2.4 mg given once a week, the same dose used in SELECT. It reduces inflammation through the routes above: fewer inflammatory signals from immune cells and fat tissue, a calmer blood vessel lining, and less liver inflammation. The result is a lower hsCRP, which is the marker most people see on their own lab reports. For the wider causes of raised CRP, see our overview of chronic inflammation and what drives it.

Emerging Therapeutic Applications

Non-Alcoholic Fatty Liver Disease / MASH

MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) is fundamentally an inflammatory liver disease driven by lipotoxicity and immune activation. In the phase II trial led by Philip Newsome (NEJM, 2021), semaglutide produced histological resolution of MASH (normalization of liver inflammation) in 59% of patients compared to 17% on placebo [6].

The phase 3 ESSENCE trial (Sanyal et al., NEJM, 2025) confirmed higher rates of MASH resolution and fibrosis improvement than placebo, and the FDA granted semaglutide accelerated approval in 2025 for adults with MASH and moderate to advanced liver fibrosis. The anti-inflammatory effects in the liver go beyond weight loss, with direct hepatoprotective signaling through GLP-1 receptors on hepatocytes and Kupffer cells. Hepatologists and gastroenterologists usually manage this use.

Psoriasis and Psoriatic Arthritis

Psoriasis is driven by TNF-alpha, IL-17, and IL-23, and it carries a heavy symptom burden, according to Egeberg and colleagues (British Journal of Dermatology, 2020) [7]. Case reports and small studies describe psoriasis improvement in patients starting a GLP-1 agonist for diabetes or weight management, and obesity itself worsens psoriasis. Larger randomized trials are needed before GLP-1 drugs can be called a psoriasis treatment.

For now, dermatologists and rheumatologists treat psoriasis with topical therapy, phototherapy and biologics, with a GLP-1 drug considered when obesity or diabetes is also present. Our psoriasis condition page and the guide to psoriasis treatment options cover the established approaches.

Neurodegenerative Disease

Neuroinflammation is a core feature of Alzheimer’s and Parkinson’s disease. GLP-1 receptors are expressed on neurons and microglia (the brain’s immune cells). Preclinical data shows that GLP-1 agonists reduce microglial activation, amyloid-beta deposition, and tau phosphorylation. The phase 3 trials of oral semaglutide in early Alzheimer’s disease, EVOKE and EVOKE+, reported in late 2025 that the drug did not slow disease progression, so this use is not supported despite the promising animal data.

Chronic Kidney Disease

The FLOW trial (Perkovic et al., NEJM, 2024) demonstrated that semaglutide reduced the risk of kidney disease progression by 24% in patients with type 2 diabetes and chronic kidney disease. The anti-inflammatory effects on renal tubular cells and glomerular endothelium likely contribute to this protection beyond glycemic control [8].

Heart Failure

Semaglutide improved symptoms, physical function, and exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF) and obesity in the STEP-HFpEF trial led by Mikhail Kosiborod (NEJM, 2023). CRP also fell further on semaglutide than on placebo. Systemic inflammation is a key driver of HFpEF pathophysiology, and GLP-1 agonist anti-inflammatory effects likely contributed to the benefit.

Important Caveats

GLP-1 agonists are powerful medications with significant side effects that must be weighed against potential anti-inflammatory benefits:

• GI side effects: Nausea, vomiting, and diarrhea affect 20 to 40% of patients, particularly during dose titration. Most resolve with slow titration but can be limiting. Our overview of semaglutide side effects covers them in more depth.
• Pancreatitis risk: Small but real increased risk of acute pancreatitis. Contraindicated in patients with a history of pancreatitis.
• Gallbladder disease: Increased risk of cholelithiasis (gallstones), particularly with rapid weight loss.
• Thyroid concerns: Medullary thyroid carcinoma risk observed in rodent studies (not confirmed in humans). Contraindicated in patients with personal or family history of MTC or MEN2.
• Muscle loss: Rapid weight loss includes lean mass loss (25 to 40% of total weight lost is lean mass). Resistance training and adequate protein intake are essential countermeasures, as our piece on GLP-1 muscle loss explains.
• Cost: $800 to $1,500 a month without insurance. Coverage is expanding but remains inconsistent, especially for obesity-only indications, and the semaglutide cost breakdown tracks how pricing varies.

Using GLP-1 agonists purely for anti-inflammatory purposes in patients without diabetes, obesity, or cardiovascular disease is not currently supported by guidelines. The risk-benefit calculation requires a clear clinical indication.

Who Prescribes GLP-1 Agonists for Inflammation-Related Conditions?

GLP-1 agonists are prescribed by physicians, nurse practitioners and physician assistants, most often in primary care, endocrinology, obesity medicine and cardiology. Hepatologists use semaglutide for MASH, nephrologists consider it in diabetic kidney disease, and functional and integrative medicine practices often offer GLP-1 programs alongside nutrition and lab monitoring.

A careful prescriber starts with history, current medications and baseline labs such as hsCRP, HbA1c, kidney function and lipids, and then rechecks them after several months. They should explain whether the drug is brand name or compounded, why it fits your diagnosis, and how side effects will be managed during dose increases.

The compounded semaglutide treatment guide explains how pharmacy-made versions differ from the approved drug, and the compounded tirzepatide guide does the same for the dual agonist. To compare providers, the national directory of peptide therapy clinics lists practices that record GLP-1 and other peptide treatments, and the peptide therapy overview sorts approved drugs from experimental ones.

Listing order in the directory is not paid ranking, Featured slots are labeled and capped, and Verified means a clinic completed credential checks rather than paid more. Regenerated.com is free for patients, and inclusion in the directory is not an endorsement. The guide to Featured, Verified and organic listings explains each label.

What This Means for Regenerative Health

The GLP-1 agonist story illustrates a broader principle: many chronic diseases share inflammatory roots. A drug developed for diabetes turns out to protect the heart, liver, and kidneys because chronic low-grade inflammation is a common driver of all these conditions, while the brain results so far are a reminder that a lab signal does not always become a clinical benefit.

For the regenerative health space, GLP-1 agonists represent a pharmacological bridge between metabolic optimization and immune modulation. They are not “natural,” but they act on physiological pathways (incretin signaling, immune cell polarization, endothelial protection) that evolution built into the body. As evidence accumulates, their role is likely to expand beyond glucose control, one tested indication at a time.

Frequently Asked Questions

Do GLP-1 drugs reduce inflammation?

Yes, GLP-1 drugs reduce markers of inflammation in people with obesity, diabetes or heart disease. In the SELECT trial, semaglutide 2.4 mg weekly lowered hsCRP by 37.8% more than placebo and reduced major cardiovascular events by 20%. Part of the effect comes from weight loss and part from GLP-1 receptors on immune cells and blood vessels. They are not approved as a general anti-inflammatory, and data in lean, healthy adults is limited.

How does GLP-1 reduce inflammation?

GLP-1 reduces inflammation by activating receptors on macrophages, T cells, blood vessel walls and liver cells. This shifts macrophages toward an anti-inflammatory M2 state, dampens NF-kB signaling, lowers adhesion molecules such as VCAM-1 and ICAM-1, and reduces inflammatory visceral fat. Animal studies also show a stronger gut barrier with less endotoxin entering the blood. Together these changes lower blood markers such as hsCRP, IL-6 and TNF-alpha.

How long does it take semaglutide to lower inflammation?

Semaglutide lowers inflammation markers within months. In SELECT, hsCRP was already clearly lower than placebo at 20 weeks and stayed lower through 104 weeks, and the cardiovascular event curves separated within the first year. Individual responses vary with dose, starting CRP and weight change, so clinicians usually recheck hsCRP and other labs after several months on a stable dose rather than after the first few injections.

Can GLP-1 agonists help autoimmune diseases like psoriasis?

GLP-1 agonists may help some people with psoriasis, but the evidence is thin. Case reports and small studies describe skin improvement, especially in people who also have obesity or type 2 diabetes, and no large randomized trial has confirmed it. For rheumatoid arthritis, inflammatory bowel disease and other autoimmune conditions, research is earlier still. Standard treatments such as biologics remain the main options, with a GLP-1 drug added when a metabolic indication also exists.

Can I get a GLP-1 prescription just for inflammation?

A GLP-1 prescription for inflammation alone would be off label and is not supported by current guidelines. FDA approvals cover type 2 diabetes, chronic weight management, cardiovascular risk reduction in eligible adults, and for semaglutide, MASH with moderate to advanced fibrosis. A clinician may consider one when you have one of those indications plus raised inflammatory markers. Expect baseline labs, a discussion of side effects and cost, and follow-up testing.

Related Reading

• Psoriasis: The Evidence-Based Guide
• Chronic Pain: The Evidence-Based Guide
• Erectile Dysfunction and Heart Health: The Cardiovascular Connection
• Psoriasis Biologics: How They Work and Which to Choose

Sources

1. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. doi:10.1016/j.cmet.2018.03.001 ↩
2. Ridker PM, Lei L, Engel S, et al. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: further rationale for the development of targeted anti-inflammatory therapies. Eur Heart J. 2020;41(23):2153-2163. doi:10.1093/eurheartj/ehz542 ↩
3. Rakipovski G, Rolin B, Nohr J, et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-/- and LDLr-/- mice by a mechanism that includes inflammatory pathways. JACC Basic Transl Sci. 2018;3(6):844-857. doi:10.1016/j.jacbts.2018.09.004 ↩
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 ↩
5. Hogan AE, Gaoatswe G, Lynch L, et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia. 2014;57(4):781-784. doi:10.1007/s00125-013-3145-0 ↩
6. Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. doi:10.1056/NEJMoa2028395 ↩
7. Egeberg A, Loft N, Zachariae C, et al. Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults. Br J Dermatol. 2020;183(1):128-138. doi:10.1111/bjd.18622 ↩
8. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109-121. doi:10.1056/NEJMoa2403347 ↩